###begin article-title 0
###xml 77 85 <span type="species:ncbi:9606">Patients</span>
Prognostic Significance and Clinicopathological Associations of COX-2 SNP in Patients with Nonsmall Cell Lung Cancer
###end article-title 0
###begin p 1
Recommended by Frederick E. Domann
###end p 1
###begin p 2
###xml 0 10 0 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Background</italic>
###xml 490 497 490 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Methods</italic>
###xml 625 632 625 632 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Results</italic>
###xml 714 715 714 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 731 732 731 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 748 749 748 749 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 916 917 916 917 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 949 950 949 950 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1140 1151 1140 1151 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Conclusions</italic>
###xml 72 80 <span type="species:ncbi:9606">patients</span>
###xml 245 253 <span type="species:ncbi:9606">patients</span>
###xml 335 343 <span type="species:ncbi:9606">patients</span>
###xml 571 579 <span type="species:ncbi:9606">patients</span>
###xml 1120 1128 <span type="species:ncbi:9606">patients</span>
###xml 1211 1219 <span type="species:ncbi:9606">patients</span>
###xml 1325 1333 <span type="species:ncbi:9606">patients</span>
###xml 1436 1444 <span type="species:ncbi:9606">patients</span>
Background. To further improve the screening, diagnosis, and therapy of patients with nonsmall cell lung cancer (NSCLC) additional diagnostic tools are urgently needed. Gene expression of Cyclooxygenase-2 (COX-2) has been linked to prognosis in patients with NSCLC. The role of the COX-2 926G>C Single Nucleotide Polymorphism (SNP) in patients with NSCLC remains unclear. The aim of this study was to investigate the potential of the COX-2 926G>C SNP as a molecular marker in this disease. Methods. COX-2 926G>C SNP was analyzed in surgically resected tumor tissue of 85 patients with NSCLC using a PCR-based RFLP technique. Results. The COX-2 926G>C SNP genotypes were detected with the following frequencies: GG n = 62 (73%), GC n = 20 (23%), CC n = 3 (4%). There were no associations between COX-2 SNP genotype and histology, grading or gender detectable. COX-2 SNP was significantly associated with tumor stage (P = .032) and lymph node status (P = .016, Chi-square test). With a median followup of 85.9 months, the median survival was 59.7 months. There were no associations seen between the COX-2 SNP genotype and patients prognosis. Conclusions. The COX-2 926G>C SNP is detectable at a high frequency in patients with NSCLC. The COX-2 926G>C SNP genotype is not a prognostic molecular marker in this disease. However, patients with the GC or CC genotype seem more susceptible to lymph node metastases and higher tumor stage than patients with the GG genotype. The results suggest COX-2 926G>C SNP as a molecular marker for lymph node involvement in this disease.
###end p 2
###begin title 3
1. Introduction
###end title 3
###begin p 4
###xml 164 165 164 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 167 168 167 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 328 329 328 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 15 22 <span type="species:ncbi:4097">tobacco</span>
###xml 359 367 <span type="species:ncbi:9606">patients</span>
###xml 560 568 <span type="species:ncbi:9606">patients</span>
The smoking of tobacco is the most prevalent cause of lung cancer, which is the leading cause of cancer mortality in the world towards the end of the 20th century [1, 2]. Each year approximately 200 000 new cases of lung cancer are diagnosed in the United States, and there were over 160 000 lung cancer related deaths in 2008 [3]. The only treatment to cure patients with nonsmall cell lung cancer (NSCLC) is radical surgery, but the 5-year survival rate still remains poor. However, the concept of individualized treatment based on genetic differences among patients promises to provide improved treatment outcomes. Thus, the molecular mechanisms involved in carcinogenesis and pharmacogenetics have to be studied so that tailored treatments can be discovered and developed.
###end p 4
###begin p 5
###xml 91 92 91 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 260 261 260 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 262 263 262 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 450 451 450 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 453 455 453 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 649 651 649 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 736 738 736 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 740 742 740 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 757 759 757 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 770 772 770 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 787 789 787 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 801 803 801 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 812 814 812 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 816 818 816 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 848 850 848 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 851 853 851 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
Inflammation has been recognized as a contributing factor in pathogenesis of many cancers [4]. Epidemiologic studies have shown that prolonged use of nonsteroidal anti-inflammatory drugs (NSAIDs) reduces the risk of a variety of cancers including lung cancer [5-8]. Cyclooxygenases (COXs, also named prostaglandin endoperoxide synthases or PTGSs) are the key enzymes in the conversion of arachidonic acid to prostaglandin (PG) and other eicosanoids [9, 10]. Two isoforms have been identified; COX-1 is consistently expressed in nearly all cells whereas COX-2 is normally undetectable but induced under circumstances such as inflammation and cancer [11]. Overexpression of COX-2 has been reported in several cancers, such as colorectal [12, 13], pancreatic [14], breast [15], esophageal [16], gastric [17], lung [18, 19], and several other cancers [20-23].
###end p 5
###begin p 6
###xml 379 381 379 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 418 420 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 421 423 421 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 443 445 443 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 447 449 447 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 592 594 592 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 57 62 <span type="species:ncbi:9606">human</span>
###xml 209 217 <span type="species:ncbi:9606">patients</span>
Single nucleotide polymorphisms (SNPs) are common in the human genetic pool, and there is growing evidence suggesting that genetic polymorphisms play a role in the variability of drug response and toxicity in patients. A predictive value concerning the response to chemotherapy treatment has been reported for certain genetic SNPs in several tumors, for example, gastric cancer [24], breast cancer, colorectal cancer [25-27], and lung cancer [28, 29]. Earlier studies have already shown that COX-2 SNPs have an impact in promoter activity and therefore influence the variability of response [30]. Papafili et al. reported a transcription alteration of the COX-2 gene caused by the COX-2 926G>C SNP in the promoter region and an increase of the levels of C-reactive protein.
###end p 6
###begin p 7
###xml 156 158 156 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 253 261 <span type="species:ncbi:9606">patients</span>
The COX-2 926G>C SNP has been investigated earlier regarding a possible increased risk of developing NSCLC, but no association could be found for this SNP [31]. No study of COX-2 926G>C polymorphism and potential prognostic significance in NSCLC cancer patients has been reported so far. Hence the rationale for conducting this study was to investigate a possible prognostic role of the COX 926G>C SNP in NSCLC.
###end p 7
###begin title 8
2. Material and Methods
###end title 8
###begin title 9
###xml 5 13 <span type="species:ncbi:9606">Patients</span>
2.1. Patients
###end title 9
###begin p 10
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 30 38 <span type="species:ncbi:9606">patients</span>
###xml 112 120 <span type="species:ncbi:9606">patients</span>
###xml 159 167 <span type="species:ncbi:9606">patients</span>
###xml 266 274 <span type="species:ncbi:9606">patients</span>
85 tumor specimens from NSCLC patients, available from a previous prospective clinical trail of 103 consecutive patients [32], were included in this study. 65 patients were male (76%) and 20 female (24%) with the median age of 62.4 years. Seventy-six (89%) of these patients were smokers.
###end p 10
###begin p 11
###xml 79 81 79 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 87 95 <span type="species:ncbi:9606">patients</span>
###xml 125 133 <span type="species:ncbi:9606">patients</span>
###xml 157 165 <span type="species:ncbi:9606">patients</span>
###xml 193 201 <span type="species:ncbi:9606">patients</span>
###xml 306 314 <span type="species:ncbi:9606">patients</span>
###xml 376 384 <span type="species:ncbi:9606">Patients</span>
###xml 499 506 <span type="species:ncbi:9606">patient</span>
According to the International Union Against Cancer (UICC) TNM classification [33], 42 patients (49%) were tumor stage I, 18 patients (21%) stage II, and 25 patients (30%) stage IIIA. 39 (46%) patients had squamous cell carcinoma, 31 (36%) had adenocarcinoma, and 15 (18%) had large cell carcinoma. All 85 patients underwent thoracic surgery, and the tumors were R0 resected. Patients with histopathologic stage 3a tumors received postoperative radiotherapy. Informed consent was obtained from each patient.
###end p 11
###begin p 12
###xml 59 66 <span type="species:ncbi:9606">patient</span>
The median followup was 85.9 months (range 63-105), and no patient was lost to followup. Tissue for gene expression analysis was obtained during surgery immediately after lung resection and before starting mediastinal lymphadenectomy. The tissues were immediately frozen in liquid nitrogen and stored at -80degreesC. Six-micrometer frozen sections were taken from blocks of tumor tissue. Starting with the first section, every fifth section was routinely stained with hematoxylin and eosin and evaluated histopathologically. Sections were pooled for analysis from areas estimated to have at least 75% malignant cells.
###end p 12
###begin p 13
###xml 83 90 <span type="species:ncbi:9606">patient</span>
###xml 133 141 <span type="species:ncbi:9606">patients</span>
###xml 185 193 <span type="species:ncbi:9606">patients</span>
The primary tumors were graded histopathologically as well differentiated (G1, one patient), moderately differentiated (G2, eighteen patients), and poorly differentiated (G3, sixty-six patients).
###end p 13
###begin title 14
2.2. DNA Extraction and Genotyping of the COX-2 926G>C SNP
###end title 14
###begin p 15
###xml 422 424 422 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
###xml 442 444 441 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
###xml 505 507 503 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
###xml 175 183 <span type="species:ncbi:9606">patients</span>
DNA was extracted from representative tumor sections using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany). The COX-2 926G>C polymorphism was analysed in tumor tissue of 85 patients with NSCLC using a PCR-based RFLP technique. Forward and reverse primers used were as follows: 5'-CAT TTA GCG TCC CTG CAA AT-3' and 5'-TAC CTT CAC CCC CTC CTT GT-3'. Briefly, an approximately 2 ng DNA was added to a reaction volume of 15 muL, containing 7.5 muL TaqMan Universal PCR Master Mix, No AmpErase UNG, and 0.75 muL custom-designed probe. Amplifications and determination of genotypes were performed using an Applied Biosystems 7500 Real Time PCR System as follows: 95degreesC (10'), 45 cycles of 93degreesC (15''), and 60degreesC (1'). PCR fragments were digested using 3 units of the restriction enzyme AciI and separated on a 3% agarose gel. A technician blinded for the clinical data performed PCR/RFLP analyses. A random sample of 20% of each polymorphism was repeated and showed 100% concordance.
###end p 15
###begin title 16
2.3. Statistical Analysis
###end title 16
###begin p 17
###xml 79 82 79 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#967;</italic>
###xml 82 83 80 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 440 442 438 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 468 470 466 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 677 678 675 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 690 691 688 689 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Statistical analyses were carried out using SPSS for Windows (version 17.0). A chi2 test was used to assess the association between categorical clinicopathologic data and COX-2 926G>C SNP genotype. Hazard ratios were used to calculate the relative risks of death. These calculations were based on the Pike estimate, with the use of the observed and expected number of events as calculated in the log-rank test statistic. The log-rank test [34] and Kaplan-Meier plots [35] were used to evaluate the association of genotypes and overall survival. Multivariate analysis was performed with the Cox proportional hazards regression model. Statistical significance was interpreted as P < .05. All P-values reported were based on two-sided tests.
###end p 17
###begin title 18
3. Results
###end title 18
###begin p 19
###xml 125 126 125 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 166 167 166 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 209 210 209 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
In the studied cohort, the COX-2 926G>C SNP genotypes were detected with the following disposition: the wild type (WT) GG in n = 62 (73%), the heterozygote SNP GC in n = 20 (23%), and the homozygote SNP CC in n = 3 (4%).
###end p 19
###begin p 20
###xml 102 103 102 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 151 159 <span type="species:ncbi:9606">patients</span>
No association between COX-2 926G>C SNP genotype and histology was seen, even though the CC genotype (n = 3) was only found in squamous cell carcinoma patients.
###end p 20
###begin p 21
###xml 466 467 466 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 482 485 482 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#967;</italic>
###xml 485 486 483 484 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 488 489 486 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 519 527 517 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1</xref>
###xml 101 109 <span type="species:ncbi:9606">patients</span>
###xml 253 261 <span type="species:ncbi:9606">patients</span>
Also, neither grading nor gender had any detectable association with the COX-2 926G>C SNP. All three patients with the genotype CC were male, but due to the small number of the CC genotype there was no statistical significance. Seventy six (89%) of the patients were smokers. There was no association between smokers and different COX 926 polymorphisms. However, in nonsmokers, the COX 926 polymorphism is more frequent than in smokers with borderline significance (P = .42 Pearson chi2; P = .056 Fisher's Exact Test) (Figure 1).
###end p 21
###begin p 22
###xml 77 78 77 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 95 98 95 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#967;</italic>
###xml 98 99 96 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 107 115 105 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2</xref>
The COX-2 926G>C SNP was significantly associated with a higher tumor stage (P = .032, Pearson chi2 test) (Figure 2). All three CC genotypes were stage IIIa, 5 CG and 13 GG genotypes were stage II, and 7 CG and 35 GG genotypes were found in stage I.
###end p 22
###begin p 23
###xml 99 100 99 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 109 112 109 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#967;</italic>
###xml 112 113 110 111 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 121 129 119 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Figure 3</xref>
###xml 142 150 <span type="species:ncbi:9606">patients</span>
###xml 251 259 <span type="species:ncbi:9606">patients</span>
###xml 327 335 <span type="species:ncbi:9606">patients</span>
###xml 376 384 <span type="species:ncbi:9606">patients</span>
Also, associations were discovered in the COX-2 926G>C polymorphism and the lymph node metastasis (P = .016, chi2 test) (Figure 3). The three patients with the CC genotype had all lymph node metastasis, two were pN1 and one was pN2. Fifteen out of 20 patients (75%) with the CG genotype had lymph node metastasis. Six of these patients were pN1 and seven pN2. Only 35% of the patients (22 of 62) with the GG genotype were suffering from lymph node metastasis.
###end p 23
###begin p 24
###xml 138 139 138 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 176 184 176 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Figure 4</xref>
With a median followup of 85.9 months, the median survival was 59.7 months (range 38-105 months). Neither the log-rank test (Mantel-Cox) (P = .848) nor the Kaplan-Meier plots (Figure 4) showed any prognostic significance for the COX-2 926G>C SNP.
###end p 24
###begin title 25
4. Discussion
###end title 25
###begin p 26
###xml 215 217 215 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
###xml 218 220 218 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39">39</xref>
###xml 298 300 298 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B40">40</xref>
###xml 301 303 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B42">42</xref>
###xml 337 339 337 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B43">43</xref>
###xml 357 359 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B44">44</xref>
###xml 369 371 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B45">45</xref>
###xml 397 399 397 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B46">46</xref>
###xml 568 576 <span type="species:ncbi:9606">patients</span>
###xml 682 690 <span type="species:ncbi:9606">patients</span>
The COX-2 pathway is important in cancer development because it is involved in the regulation of various critical cellular processes such as tumor progression, metastases, angiogenesis, and chemotherapy resistance [36-39]. Elevated COX-2 expression has been associated with poor prognoses in lung [40-42] and other cancers, such breast [43], head and neck [44], colon [45], and cervix carcinomas [46]. However, little is known about COX-2 single nucleotide polymorphisms in NSCLC. In this study, we found that the COX-2 926G>C SNP is detectable at a high frequency in patients with NSCLC. We used PCR-based RFLP protocols to analyze the COX-2 926 genotype and found that 73% of the patients had the wild type genotype (GG), 23% were heterozygote (GC) and 4% homozygote (CC) for the COX-2 926 polymorphism.
###end p 26
###begin p 27
###xml 179 181 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B47">47</xref>
###xml 218 220 218 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B48">48</xref>
###xml 521 523 521 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
Several previous studies have examined the associations of COX-2 polymorphisms and tumor diseases. In breast cancer, the COX-2 169-GG genotype was associated with increased risk [47], but the COX-2 926G>C SNP was not [48], while some tenuous evidence was found for an interaction between the C allele of the COX-2 8473 SNP with NSAIDs to reduce risk for hormone receptor positive breast cancer. In the case of NSCLC, it was suggested that the COX-2 8473SNP is associated with an increased risk of developing lung cancer [31] but COX-2 926G>C SNP was not, as already mentioned in the introduction.
###end p 27
###begin p 28
The association between smoking and the COX-2 926G>C SNP did not reach statistical significance in this study but the trend suggests the need for further investigation with larger numbers.
###end p 28
###begin p 29
###xml 89 97 <span type="species:ncbi:9606">patients</span>
###xml 211 219 <span type="species:ncbi:9606">patients</span>
Although we did not find the COX-2 926G>C SNP to be a prognostic marker for NSCLC, NSCLC patients with the GC or CC genotype were apparently more susceptible to lymph node metastases and higher tumor stage than patients with the GG genotype, suggesting that the COX-2 926G>C SNP is a molecular marker for lymph node involvement.
###end p 29
###begin article-title 30
Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention
###end article-title 30
###begin article-title 31
Global cancer statistics, 2002
###end article-title 31
###begin article-title 32
Cancer Facts & Figures 2008
###end article-title 32
###begin article-title 33
Inflammation and cancer
###end article-title 33
###begin article-title 34
Protective effect of NSAIDs on cancer and influence of COX-2 C-765G genotype
###end article-title 34
###begin article-title 35
A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence
###end article-title 35
###begin article-title 36
Aspirin use and reduced risk of fatal colon cancer
###end article-title 36
###begin article-title 37
Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review)
###end article-title 37
###begin article-title 38
Cyclooxygenases 1 and 2
###end article-title 38
###begin article-title 39
Mechanism of action of aspirin-like drugs
###end article-title 39
###begin article-title 40
###xml 20 25 <span type="species:ncbi:9606">human</span>
Cyclooxygenase-2 in human pathological disease
###end article-title 40
###begin article-title 41
###xml 53 58 <span type="species:ncbi:9606">human</span>
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
###end article-title 41
###begin article-title 42
###xml 41 46 <span type="species:ncbi:9606">human</span>
Expression of cyclooxygenase-1 and -2 in human colorectal cancer
###end article-title 42
###begin article-title 43
###xml 47 52 <span type="species:ncbi:9606">human</span>
Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer
###end article-title 43
###begin article-title 44
###xml 55 60 <span type="species:ncbi:9606">human</span>
Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer
###end article-title 44
###begin article-title 45
###xml 31 36 <span type="species:ncbi:9606">human</span>
Cyclooxygenase-2 expression in human esophageal carcinoma
###end article-title 45
###begin article-title 46
###xml 34 39 <span type="species:ncbi:9606">human</span>
Expression of cyclooxygenase-2 in human gastric carcinoma
###end article-title 46
###begin article-title 47
###xml 22 27 <span type="species:ncbi:9606">human</span>
COX-2 is expressed in human pulmonary, colonic, and mammary tumors
###end article-title 47
###begin article-title 48
###xml 34 39 <span type="species:ncbi:9606">human</span>
Expression of cyclooxygenase-2 in human lung carcinoma
###end article-title 48
###begin article-title 49
###xml 72 77 <span type="species:ncbi:9606">human</span>
Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer
###end article-title 49
###begin article-title 50
###xml 37 42 <span type="species:ncbi:9606">human</span>
Cyclooxygenase-2 is overexpressed in human cervical cancer
###end article-title 50
###begin article-title 51
###xml 112 117 <span type="species:ncbi:9606">human</span>
Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder
###end article-title 51
###begin article-title 52
###xml 95 100 <span type="species:ncbi:9606">human</span>
Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta human endometrial adenocarcinoma
###end article-title 52
###begin article-title 53
###xml 141 149 <span type="species:ncbi:9606">patients</span>
Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)-novel predictors for response and survival in gastric cancer patients
###end article-title 53
###begin article-title 54
###xml 181 189 <span type="species:ncbi:9606">patients</span>
Single nucleotide polymorphism in the 5' tandem repeat sequences of Thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients
###end article-title 54
###begin article-title 55
Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy
###end article-title 55
###begin article-title 56
A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer
###end article-title 56
###begin article-title 57
###xml 124 132 <span type="species:ncbi:9606">patients</span>
Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy
###end article-title 57
###begin article-title 58
###xml 91 99 <span type="species:ncbi:9606">patients</span>
MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer
###end article-title 58
###begin article-title 59
Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response
###end article-title 59
###begin article-title 60
Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer
###end article-title 60
###begin article-title 61
Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer
###end article-title 61
###begin article-title 62
Revisions in the international system for staging lung cancer
###end article-title 62
###begin article-title 63
Maximally selected chi square statistics
###end article-title 63
###begin article-title 64
Nonparametric estimation from incomplete observations
###end article-title 64
###begin article-title 65
###xml 30 35 <span type="species:ncbi:9606">human</span>
Targeting cyclooxygenase-2 in human neoplasia: rationale and promise
###end article-title 65
###begin article-title 66
Inhibition of cyclooxygenase (COX)-2 expression by tet-inducible COX-2 antisense cDNA in hormone-refractory prostate cancer significantly slows tumor growth and improves efficacy of chemotherapeutic drugs
###end article-title 66
###begin article-title 67
Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor
###end article-title 67
###begin article-title 68
###xml 62 66 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Suppression of intestinal polyposis in Apc(delta716) knockout mice by inhibition of cyclooxygenase 2 (COX-2)
###end article-title 68
###begin article-title 69
Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer
###end article-title 69
###begin article-title 70
###xml 161 169 <span type="species:ncbi:9606">patients</span>
Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients
###end article-title 70
###begin article-title 71
Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer
###end article-title 71
###begin article-title 72
Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer
###end article-title 72
###begin article-title 73
Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma
###end article-title 73
###begin article-title 74
Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer
###end article-title 74
###begin article-title 75
Expression of cyclooxygenase-2 (COX-2) in tumour and stroma compartments in cervical cancer: clinical implications
###end article-title 75
###begin article-title 76
A novel single nucleotide polymorphism of the cyclooxygenase-2 gene associated with breast cancer
###end article-title 76
###begin article-title 77
Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk
###end article-title 77
###begin p 78
###xml 174 175 174 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Distribution of the COX-2 926G>C SNP and wild type in smoker or nonsmoker. In nonsmoker a COX-2 926 polymorphism is borderline significant and more frequent than in smokers (P = .056 Fisher's Exact Test).
###end p 78
###begin p 79
###xml 120 121 120 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 138 141 138 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#967;</italic>
###xml 141 142 139 140 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Tumor stage and COX-2 926G>C SNP in NSCLC. The COX-2 926G>C SNP was significantly associated with a higher tumor stage (P = .032, Pearson chi2 test).
###end p 79
###begin p 80
###xml 146 147 146 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 156 159 156 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#967;</italic>
###xml 159 160 157 158 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Distribution of the COX-2 926G>C polymorphism and lymph node status. The COX-2 926G>C polymorphism is associated with a higher lymph node status (P = .016, chi2 test).
###end p 80
###begin p 81
###xml 68 76 <span type="species:ncbi:9606">patients</span>
Kaplan-Meier cumulative survival plot for nonsmall cell lung cancer patients with CC, CG, and GG COX-2 926G>C SNP. The probability of survival was not statistically different between the different genotypes.
###end p 81

